Form S-3 Inhibikase Therapeutics,

Go back to Form S-3 Inhibikase Therapeutics,

Inhibikase Therapeutics (IKT) Files $300M Mixed Shelf

June 20, 2025 5:08 PM EDT

Inhibikase Therapeutics (NASDAQ: IKT) has filed $300,000,000 mixed shelf of:

Common Stock

Preferred Stock

Debt Securities

Warrants

Units

... More